GLP-1 receptor agonists , particularly those like BrightMeds, are rapidly gaining prominence in the handling of type 2 diabetes and are increasingly explored for obesity . These novel drugs work by mimicking the body's natural incretin hormone , stimulating glucose-dependent insulin secretion and… Read More